TPD52 and lung carcinoma: Notably, emerging evidence highlights crosstalk between TPD52 and other signaling axes: the androgen receptor, for example, can inhibit lung cancer cell invasion by regulating the circ-SLCO1B7/miR-139-5p/TPD52 signaling pathway, thereby increasing sensitivity to cisplatin and effectively curbing nonsmall cell lung cancer development [47].